Pulse Biosciences Receives Sell Rating Upgrade from StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was recently upgraded to a "sell" rating by analysts at StockNews.com in a research note released on Monday.

Pulse Biosciences Stock Performance

On Monday, shares of Pulse Biosciences experienced a decline, falling by $0.51 to close at $16.09. Throughout the day, 459,987 shares were traded, exceeding the average volume of 198,258 shares. The stock's fifty-day simple moving average is currently $18.78, while its two-hundred-day simple moving average stands at $18.15. Over the past year, the stock has seen a low of $6.60 and a high of $25.00.

Institutional Trading Activity

Several institutional investors have recently adjusted their positions in Pulse Biosciences. Invesco Ltd. made a significant change, increasing its position by 1,956.7% in the fourth quarter, now holding 214,490 shares valued at $3,734,000 after acquiring an additional 204,061 shares. Vanguard Group Inc. also increased its holdings in Pulse Biosciences by 15.1%, now owning 1,146,339 shares worth $19,958,000 following an additional purchase of 150,506 shares in the same quarter. Charles Schwab Investment Management Inc. raised its stake by 193.0% during the third quarter, now possessing 148,114 shares valued at $2,598,000 after acquiring 97,565 more shares. Additionally, State Street Corp boosted its investment by 17.8% in the third quarter, owning 461,333 shares worth $8,092,000 after purchasing 69,696 shares. Panoramic Capital LLC also made a new investment in Pulse Biosciences, adding a stake valued at approximately $846,000. Institutional investors collectively own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc. is a pioneer in bioelectric medicine, specializing in the development of innovative medical technologies. The company offers the CellFX System, a versatile platform that utilizes Nano-Pulse Stimulation technology. This technology delivers rapid electrical pulses to target cells without harming surrounding tissue, which allows for treating various medical conditions.

Investment Considerations

Before considering an investment in Pulse Biosciences, investors should review analyst ratings. Currently, while the stock holds a Hold rating among analysts, there are suggestions that other stocks may provide a better opportunity for returns, according to top analysts.

Pulse, Biosciences, Stocks